With additional data on the use of nonstatin therapies now available since the ACC/AHA released the last cholesterol guidelines in 2013, the ACC has released additional guidance on their use in clinical practice.
Full results from the LEADER trial were presented at the annual meeting of the ADA, outlining significant decreases in CV risk and mortality when patients were treated with the GLP-1 agonist liraglutide
The GLP-1 agonist liraglutide has shown in the CV outcomes LEADER trial to statistically significantly reduce the risk of major adverse cardiovascular events among more than 9000 high-risk adults with T2DM.
"Burst" exercise, or short periods of high-intensity exercise, was associated with greater improvement in HbA1c, cholesterol, and BMI in patients with diabetes compared with an exercise regimen consisting of longer periods of sustained, lower-intensity exercise.
The GLP-1 agonist lixisenatide has shown no increase or decrease in the rate of major cardiovascular events in the CV outcomes trial ELIXA, and the GLP-1 agonist liraglutide has shown greater HbA1c reductions compared with SGLT-2 inhibitors, according to results of a meta-analysis.
The SGLT-2 inhibitor empagliflozin significantly reduced the risk of MI, stroke, and CV and all-cause mortality in the CV outcomes trial EMPA-REG OUTCOME, making it the first glucose-lowering agent to do so in a CV outcomes trial...could treatment of the metabolic syndrome be the reason?
More aggressive management of hypertension, with a target systolic blood pressure of less than 120 mmHg, has been shown in a landmark trial to result in a significant reduction of cardiovascular events and a lowered risk of mortality.
The CardioMetabolic Health Alliance issues consensus paper recommending a new patient care model to better identify patients at risk for metabolic syndrome before it develops and recognizes subtypes and stages of metabolic syndrome.
Dr. Anne Peters, Professor at Keck School of Medicine and Director of Clinical Diabetes Programs at USC in Los Angeles, will discuss what is new in diabetes technology and how today's innovations can be used to drive behavior change.
In his keynote presentation, Dr. Turnbaugh will present information from his ongoing studies in the laboratory and current work in the field attempting to understand the mechanisms linking the gut microbiome to metabolic disease.
“The value of a technique, in part, is if it can show you what is likely to work and not likely to work,” according to Dr. Steven E. Nissen, Chairman, Department of Cardiovascular Medicine at the Cleveland Clinic.
Drs. Libby and Ridker address CHD risk factors beyond lipids by presenting their research on the role of inflammation in the pathophysiology of atherosclerosis and the impact anti-inflammatory therapies under investigation may have on reducing cardiovascular event rates.
Dr. Turnbaugh discusses recent studies implicating gut microbes in obesity, how these interactions are influenced by host and environmental factors, and the potential mechanisms responsible, as well as opportunities for clinical intervention in the coming years.